International Stereotactic Radiosurgery Society

Become a member | Log In | Contact us

Webinars

The ISRS began a serie of Webinars, starting October 11th, 2016.

These Webinars are organized through a specific online service. If you wish to attend these sessions, you will be asked to register first, but you also need to have a device (computer, smartphone, tablet) that meets specific requirements. Click here to check your system

After the webinar, a video replay is made available to ISRS members.

Next Webinars

January 25, 2018

Optimal sequencing of stereotactic radiosurgery and systemic therapies in the management of patients with brain metastases by Mark PINKHAM

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 11:00 am (Brasilia) - 10:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 11:00pm (Brisbane)

Stereotactic radiosurgery (SRS) is a standard approach for appropriately-selected patients with a limited number of brain metastases (BM) at diagnosis.  In recent years, treatment paradigms have been changing because SRS utilisation has expanded and systemic therapies with intracranial penetration are emerging.  Data describing activity of common targeted and immunotherapy agents in the brain will be reviewed.  The rationale for individualised treatment selection and optimal sequencing with SRS will be discussed.

February 08, 2018

Everything You Always Wanted to Know About Radiosurgery of AVM (But Were Afraid to Ask) by Mikhail CHERNOV

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 10:00 am (Brasilia) - 10:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 11:00pm (Brisbane)

Stereotactic radiosurgery (SRS) is an effective management option of intracranial AVM. It is particularly indicated for deep-seated or critically-located lesions. Successful treatment results in obliteration of the nidus within 1-3 years (so-called “latency period”) due to gradual thickening of the vessel wall. In small AVM (® is used. In general, it seems that for Spetzler-Martin grades I-II AVM microsurgical resection is the treatment of choice, for grade III single-staged SRS may be considered, whereas for grade IV-V either staged SRS or combined treatment is reasonable. However, this scheme is very general, and determination of the optimal treatment strategy for such patients depends on the various additional parameters.

February 26, 2018

Brain Metastasis: An Update on Management Principles by Rupesh KOTECHA & Minesh MEHTA

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 11:00 am (Brasilia) - 10:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 11:00pm (Brisbane)

Over the past couple of years, there have been several new developments regarding the role of surgery, whole-brain radiotherapy, stereotactic radiosurgery, and chemotherapy in the management of patients with brain metastasis. Individually, each study has provided new perspectives on the roles of each of the modalities in the treatment of these patients but collectively they have also brought new questions to light. In the following webinar, Dr. Mehta and Dr. Kotecha will review the recent trials to provide the participants with an updated knowledge base about how to approach patients with brain metastasis in the contemporary era.

March 09, 2018

SBRT for Oligometastatic disease by Marta SCORSETTI

12:00 pm (Dublin, Edinburgh, Lisbon, London) - 1:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00pm (Brisbane)

SBRT in oligometastatic patients is an extremely exciting topic, as it may represent a fantastic opportunity to improve cancer patients' prognosis and also to possibly cure some of them. I will try to define who is the oligometastatic patient and I will show what evidence we currently have of local ablative approaches integrating the traditional systemic therapies. I will also talk about what challenges we are facing at the moment and that we need to address in the near future, to be able to benefit from this new approach.

April 05, 2018

Strategies of Sharpening Dose Fall-off for Stereotactic Radiosurgery of Brain Lesions by Lijun MA

1:00 pm (Dublin, Edinburgh, Lisbon, London) - 2:00 pm CET (Amsterdam, Berlin, Bern, Paris, Rome, Stockholm, Vienna) - 8:00 am (Eastern time - New York, Canada) - 9:00 am (Brasilia) - 9:00 pm (Tokyo) - 5:00 am (Pacific time - Los Angeles) - 10:00pm (Brisbane)

A sharp dose fall-off is the hall-mark of intracranial stereotactic radiosurgery (SRS).  This dosimetric feature had enabled high-dose focal radiation to be safely and effectively delivered toward a single or multiple brain lesions in one or few treatments.  In this presentation,  I will highlight physical principles, user strategies as well as some historical endeavors and controversies in quantifying and enhancing the dose fall-off for SRS of simple and complex brain lesions.  On-going developments and emerging technologies related to the topic will be also discussed.